Research Papers

25 of 283 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Mesenchymal stroma/stem cells: Haematologists' friend or foe?
Nachmias B; Zimran E; Avni B.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Haematological variables and risk of future venous thromboembolism in the British Regional Heart Study on men. Combined…
Wannamethee SG; Papacosta O; Lennon L; Whincup PH; Rumley A; Lowe GDO.
Br J Haematol (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia prol…
Imbery JF; Heinzelbecker J; Jebsen JK; McGowan M; Myklebust C; Bottini N; Stanford SM; Skånland SS; Tveita A; Tjønnfjord GE; Munthe LA; Szodoray P; Nakken B.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.
Sánchez-Vizcaíno F; Tamayo C; Ramos F; Ramos F; Láinez-González D; Serrano-López J; Barba R; Martin MD; Llamas P; Alonso-Dominguez JM.
Br J Haematol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Calabretta E; Guidetti A; Ricci F; Di Trani M; Monfrini C; Magagnoli M; Bramanti S; Maspero D; Morello L; Merli M; Di Rocco A; Graudenzi A; Derenzini E; Antoniotti M; Rossi D; Corradini P; Santoro A; Carlo-Stella C.
Br J Haematol (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than pa…
Merli P.
Br J Haematol (Unknown)
Published: 2022
1/6 Transparent
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution…
Brivio E; Cossio A; Borra D; Silvestri D; Prunotto G; Colombini A; Verna M; Rizzari C; Biondi A; Conter V; Valsecchi MG; Balduzzi A.
Br J Haematol (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients …
Marchetti M; Barelli S; Gleich T; Gomez FJ; Goodyer M; Grandoni F; Alberio L.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Checkpoint CD47 expression in classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Löf L; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G.
Br J Haematol (Unknown)
Published: 2022
2/6 Transparent
Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
Jobson D; McCormack CJ; Mar V; Tam C; Henderson MA.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
Mori A; Onozawa M; Tsukamoto S; Ishio T; Yokoyama E; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T.
Br J Haematol (Unknown)
Published: 2022
2/6 Transparent
Cardiovascular disease in hereditary haemophilia: The challenges of longevity.
Shapiro S; Benson G; Evans G; Harrison C; Mangles S; Makris M.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplos…
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
TTP: From empiricism for an enigmatic disease to targeted molecular therapies.
Graça NAG; Joly BS; Voorberg J; Vanhoorelbeke K; Béranger N; Veyradier A; Coppo P.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Branford S.
Br J Haematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Gallipoli P; Clark RE; Byrne J; Apperley JF; Milojkovic D; Foroni L; Goldman JM; O'Brien S.
Br J Haematol (Unknown)
Published: 2022
2/6 Transparent
Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.
Di Paola A; Palumbo G; Tortora C; Argenziano M; Catanoso M; Di Leva C; Ceglie G; Perrotta S; Locatelli F; Rossi F.
Br J Haematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Identification of the minimum requirements for successful haematopoietic stem cell transplantation.
Nishi K; Sakamaki T; Sadaoka K; Fujii M; Takaori-Kondo A; Chen JY; Miyanishi M.
Br J Haematol (Unknown)
Published: 2021
3/6 Transparent
Data Funding Declared
Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Associ…
Di Minno MND; Napolitano M; Giuffrida AC; Baldacci E; Carulli C; Boccalandro E; Bruno C; Forneris E; Ricca I; Passeri W; Martinelli M; Rivolta GF; Solimeno LP; Martinoli C; Rocino A; Pasta G; Italian Association of Haemophilia Centres Musculoskeletal Working Group.
Br J Haematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phas…
Cull G; Burger JA; Opat S; Gottlieb D; Verner E; Trotman J; Marlton P; Munoz J; Johnston P; Simpson D; Stern JC; Prathikanti R; Wu K; Novotny W; Huang J; Tam CS.
Br J Haematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated …
Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ.
Br J Haematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberration…
Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE.
Br J Haematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia.
Nardo-Marino A; Petersen J; Brewin JN; Birgens H; Williams TN; Kurtzhals JAL; Rees DC; Glenthøj A.
Br J Haematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.
Leoncini L.
Br J Haematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared